Phase 1 studies comparing safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01 (a rituximab biosimilar) to reference rituximab in Chinese patients with CD20-positive B-cell lymphoma

OBJECTIVE: This study aimed to compare the pharmacokinetic, pharmacodynamic and safety profiles of HLX01 (a rituximab biosimilar) and reference rituximab sourced from China (MabThera(®); rituximab-CN). METHODS: Here we report the results of two phase 1 studies. In the phase 1a, open-label, dose-esca...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yuankai, Zhang, Qingyuan, Han, Xiaohong, Qin, Yan, Ke, Xiaoyan, Su, Hang, Liu, Li, Fu, Jinxiang, Jin, Jie, Feng, Jifeng, Hong, Xiaonan, Zhang, Xiaohong, Wu, Depei, Jiang, Bin, Dong, Xiaodong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286892/
https://www.ncbi.nlm.nih.gov/pubmed/34321836
http://dx.doi.org/10.21147/j.issn.1000-9604.2021.03.11

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286892/
https://www.ncbi.nlm.nih.gov/pubmed/34321836
http://dx.doi.org/10.21147/j.issn.1000-9604.2021.03.11

Ejemplares similares